US life insurers' offshore reinsurance liabilities breach $1tn
Unlock the Editor's Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
US life insurers have shifted more than $1tn of liabilities offshore, offloading more risk to foreign jurisdictions despite regulators' concerns about protections for retirement savings and broader financial stability.
Private capital-owned groups such as Apollo's Athene and KKR's Global Atlantic, as well as traditional insurers such as Prudential and MassMutual, last year moved more than $130bn of liabilities to offshore reinsurers primarily based in Bermuda, according to new figures from S&P Global Market Intelligence.
US life insurers' and annuity providers' total reserves ceded abroad, including liabilities moved to jurisdictions such as the Cayman Islands and Barbados, reached $1.1tn by the end of 2024, S&P said.
The reinsurance deals come despite regulators and credit rating agencies warning of rising risks, with questions about whether the reinsurers have adequate assets to back up their promises to policyholders.
Scrutiny intensified last year after the meltdown of 777 Re, a private equity-owned Bermudian reinsurer that had taken on significant exposure to assets connected to Josh Wander's Miami-based investment company, which collapsed last year after a failed attempt to buy football club Everton.
The fallout hit US insurers that had ceded billions of dollars in assets to 777 Re through risk-transfer deals, and Utah's insurance commissioner asked a judge to place an insurer and two reinsurers connected with 777 Re into rehabilitation in March.
Life insurers have used the global reinsurance sector for many years to spread their risks, such as customers living longer than expected. Read More What if you can't afford long-term care?
But so-called asset-intensive or funded reinsurance, where the risks associated with both liabilities and the assets backing them are sent offshore, is raising concerns among regulators.
Insurers' growing ties with alternative investment managers could also create conflicts of interest, according to Fitch Ratings.
Athene, acquired in 2022 by Apollo, had transferred the risk associated with liabilities worth $193bn to its offshore affiliates by the end of 2024, according to a Fitch analysis of regulatory filings for the Financial Times, in a strategy that helped to fuel a record-breaking year of US annuity sales for the insurer.
But traditional insurers such as MassMutual, with asset manager Centerbridge, and Prudential, with private equity group Warburg Pincus, have also made greater use of vehicles, in a sign of how private equity groups have reshaped retirement savings.
Following the 777 scandal, Bermuda's financial watchdog said that it would more closely monitor connected-party assets. Both the Bermuda Monetary Authority and the US National Association of Insurance Commissioners have also recently announced new supervisory measures, such as additional reporting requirements on insurers' investment portfolios, which analysts at Fitch told the Financial Times had helped to address their concerns.
Suzanne Williams-Charles, chief executive of a trade body for Bermuda reinsurers, told the Financial Times: 'We believe that the Bermuda reinsurance market — specifically, the life sector — does not pose a systemic risk.'
But fresh concerns have emerged in other offshore jurisdictions over capital requirements, with prominent Bermuda reinsurers recently seeking to distance themselves from practices in the Cayman Islands.
Athene chief executive James Belardi warned investors earlier this year of 'unabated growth' in the Cayman Islands, where he said that $150bn of insurance reserves were 'supported by a fraction of the capital required by the US or Bermuda'.
The research from S&P found that total reserves ceded by US life insurers and annuity providers to reinsurers, including onshore groups, grew to more than $2.4tn at the end of last year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
23 minutes ago
- Associated Press
Mississippi partners with tech giant Nvidia for AI education program
The state of Mississippi and technology giant Nvidia have reached a deal for the company to expand artificial intelligence training and research at the state's education institutions, an initiative to prepare students for a global economy increasingly driven by AI, Gov. Tate Reeves announced Wednesday. The memorandum of understanding, a nonbinding agreement, between Mississippi and the California-based company will introduce AI programs across the state's community colleges, universities and technical institutions. The initiative will aim to train at least 10,000 Mississippians using a curriculum designed around AI skills, machine learning and data science. Mississippi now joins Utah, California and Oregon, which have signed on to similar programs with Nvidia. 'This collaboration with Nvidia is monumental for Mississippi. By expanding AI education, investing in workforce development and encouraging innovation, we, along with Nvidia, are creating a pathway to dynamic careers in AI and cybersecurity for Mississippians,' Reeves said. 'These are the in-demand jobs of the future — jobs that will change the landscape of our economy for generations to come. AI is here now, and it is here to stay.' The agreement does not award any tax incentives to Nvidia, but Reeves said the state would provide funding for the initiative. Still, he did not foresee having to call a special legislative session in order to pay for it. Reeves said officials and Nvidia were still determining the exact dollar figure the project would require, but the state would spend as much as it took to reach its goal of training at least 10,000 Mississippians. Some of the funding may come from $9.1 million in grants to state institutions of higher learning through the Mississippi AI Talent Accelerator Program, which Reeves announced last week. Nvidia designs and supplies graphics processing units (GPUs), and the Mississippi program will focus on teaching people to work with GPUs. The company has seen growing demand for its semiconductors, which are used to power AI applications. Now the world's most valuable chipmaker, Nvidia announced in April that it will produce its AI supercomputers in the United States for the first time. Louis Stewart, head of strategic initiatives for Nvidia's global developer ecosystem, said the Mississippi program is part of a larger effort to bolster the United States' position as the global leader in artificial intelligence. 'Together, we will enhance economic growth through an AI-skilled workforce, advanced research, and industry engagement, positioning Mississippi as a hub for AI-driven transformation to the benefit of its communities.' ___ This story was originally published by Mississippi Today and distributed through a partnership with The Associated Press.
Business Journals
31 minutes ago
- Business Journals
Layoffs follow acquisition announcement at Austin tech company Khoros
A local company that has a platform to help other businesses engage with customers on social media has laid off a large percentage of its Austin-based employees. The story also includes background about the company's recent acquisition.
Yahoo
38 minutes ago
- Yahoo
Liver-Assessment Tool Hepatoscope® Steadily Expands Installed-Base Validating Its Clinical and Commercial Viability
E-Scopics' Ultraportable, Software-Based Hepatoscope In Use Across Leading Institutions and Clinics AIX-EN-PROVENCE, France, June 20, 2025--(BUSINESS WIRE)--After successfully exhibiting its unique software-based liver assessment tool Hepatascope at the DDW Convention in San Diego and the EASL Conference in Amsterdam, the France-based medical ultrasound company E-Scopics will demonstrate the technology at the June 2025 American Diabetes Association Conference in Chicago. The technology is seeing expanded adoption, with the company reporting that it has established the technology in a number of important sites in the US and Europe, validating its clinical and commercial viability. In the span of a few short years, the company has successfully adapted its premium ultrafast imaging point-of-care systems into GI and primary care, putting the system into the hands of a growing number of users who recognize its clinical value and importance in improving the standard of care for patients. In the process, E-Scopics has completely disrupted the field of portable ultrasound by leveraging proprietary technology using software-based image reconstruction. In 2023 E-Scopics began to commercialize its first product, Hepatoscope, both in the USA and in EMEA countries. The company's mid-term goal is to increase its footprint globally, starting its expansion to most European countries, where patients at risk of chronic liver diseases are. Hepatoscope continues to gain recognition as an alternative to legacy technology, from major institutions and all-size healthcare institutions across the USA. E-Scopics Founder and CEO Claude Cohen-Bacrie, who brings deep experience developing and taking to market cutting-edge ultrasound technologies, commented, "Our ambition is to bring premium quantitative ultrasound modalities and tools at the point-of-care, in the hands of non-ultrasound expert users, for the benefit of healthcare systems and patients. Making patients' journey and care pathways simpler and more efficient is our priority. We are so pleased that our backers- both leading users who understand the clinical and business partners who get the commercial potential, are in it for the long haul- and really excited about it." The company recognized MASLD was on the rise globally, and the need to bring the healthcare community a less expensive, more portable, and easier-to-use tool to accurately screen for the disease. It was very deliberate, developing a tool that was simple to use and reducing costs. The Hepatoscope application can easily be loaded onto a consumer laptop or tablet and rapidly deployed in the field. In addition to ease-of-use, the company saw Ultrasound-as-a-Service model as means to open access to any clinic via an affordable monthly or pay-per-use subscription, innovating on the business side. Cohen-Bacrie continued, "We see a healthier patient population coming out of a world where there is healthy business competition which drives innovation. We would not be talking about elastography outside of this important competitive environment. Especially where liver assessment is concerned, patients really need it, clinicians are asking for better and more affordable tools, and the FDA and payers endorse it." The numbers bear the need out. Approximately 1.5 million patients have been diagnosed with metabolic dysfunction associated steatohepatitis (MASH) in the U.S., and it is estimated that the precursor to MASH—metabolic dysfunction-associated steatotic liver disease or MASLD—will affect more than half of all American adults by 2040. The MASLD spectrum ranges from a simple, generally nonprogressive fat buildup in the liver all the way to MASH, which can lead to cirrhosis, hepatocellular carcinoma, and death. The economic burden attributed to effects of MASLD in the U.S. exceeds $100 billion annually. Therefore, it is crucial to identify these patients and take care of them as early as possible. "As consumers we've become conditioned to expect the latest and greatest personal computing and communications tools, they simply make us more efficient in day-to-day tasks, said Dr. Julio Gutierrez, Associate Professor of Medicine at Scripps Center for Organ Transplant in La Jolla, CA and an early adopter of Hepatoscope. "I think of E-Scopics like Apple and have come to expect continuous innovation, and the clinical impact has been significant." Dr. Cyrielle Caussy MD, PhD, Professor of Nutrition and an Endocrinologist-Diabetologist at Lyon 1 University and Lyon South Hospital in France, asserted, "In the endocrine and diabetology practice, approximately 80% of patients screened show low liver stiffness, which means they can be reassured without further referral or testing. By reducing the time between initial screening and specialty care, the Hepatoscope improves both the efficiency and quality of patient management. For high-risk patients, we can initiate care pathways much earlier, potentially slowing or halting the progression of liver disease. At the same time, for low-risk individuals, we avoid unnecessary referrals, which frees up resources and improves overall healthcare system efficiency. Importantly, patients appreciate the immediate feedback they receive, which encourages compliance with treatment plans and lifestyle modifications." E-Scopics will demonstrate Hepatoscope at the American Diabetes Association annual conference in Chicago in Booth #3527. Visitors may walk in and also book a time by emailing About E-Scopics: E-Scopics S.A.S is a MedTech company headquartered in France. The company advances the accessibility, affordability, and ease of use of premium ultrasound tools at the point of care. Its agile software platform has dematerialized and automated ultrasound imaging technologies. Ultrasound-as-a-Service products derived from this platform are specific Apps commercialized with pay-per-use or subscription business models. The company's first product, the Hepatoscope, leverages quantitative imaging capabilities to help any clinician assess liver fibrosis and steatosis—important markers of MASLD-MASH—non-invasively at the bedside. To learn more, visit View source version on Contacts Dan ConleyBeacon Communicationsdconley@ 312-593-8461 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
